FITLIFE BRANDS, INC. FTLF

Healthcare SIC 2833 - Medicinal Chemicals & Botanical Products NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Medicinal and Botanical Manufacturing derived Nasdaq

FitLife Brands, Inc. (the "Company") is a provider of innovative and proprietary nutritional supplements and wellness products for health-conscious consumers marketed under the following brand names: (i) NDS Nutrition, PMD Sports, SirenLabs, Core Active, Nutrology, and Metis Nutrition (together, the "NDS Products"); (ii) iSatori, BioGenetic Laboratories, and Energize (together, the "iSatori Products"); (iii) Dr. Tobias, All Natural Advice, and Maritime Naturals (together, the "MRC Products"); (iv) MusclePharm; and (v) Irwin Naturals, Applied Nutrition, and Nature's Secret (together, the "Irwin Products").

The Company distributes the NDS Products principally through franchised General Nutrition Centers, Inc. ("GNC") stores located both domestically and internationally. The iSatori Products are sold through retail locations, which include specialty and mass market retailers, as well as online directly to the end consumer. The Company distributes the MRC Products primarily online through e-commerce platforms, such as Amazon.com ("Amazon"), directly to the end consumer. MusclePharm's products are sold to both wholesale customers as well as online through various e-commerce platforms directly to the end consumer. Irwin Products are sold principally through wholesale channels in mass market and health food store segments.

Last close 8.32 2026-10-26
Market cap $78.1M 2026-06-30 share count
52-week range 8.05 - 19.95

Valuation FY2025 figures against the last close

P/S1.0x
P/E13.2x
P/FCF10.6x
EV/EBITDA7.5x
Dividend yield—
Diluted EPS0.63

Where the revenue comes from as reported in the latest 10-K

Revenue by geography

  • United States
  • Non-US
Revenue by geography, 2 categories over 2 years. The same figures are in the table below. FY2025 United States, FY2025: 77.4M (95.0%) 95% United States Non-US, FY2025: 4.1M (5.0%) 5% Non-US FY2024 United States, FY2024: 61.5M (95.4%) 95% Non-US, FY2024: 3M (4.6%) 5%
Region FY2025FY2024
United States $77.4M $61.5M
Non-US $4.1M $3.0M

As the company reported it, from the “Note 12 - Segment Information - Revenue by Geographic Area (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $81.5M$64.5M$52.7M$28.8M$27.9M$22.1M$19.1M$17.1M$17.8M$25.3M
Cost of revenue $50.0M$36.4M$31.3M$16.8M$15.4M$12.6M$11.2M$10.3M$12.7M$15.2M
Gross profit $31.5M$28.1M$21.4M$12.0M$12.5M$9.5M$8.0M$6.7M$5.1M$10.1M
SG&A $14.0M$10.0M$7.9M$6.0M$6.2M$3.0M$3.0M$3.3M$4.2M$5.0M
Total operating expenses $21.4M$15.0M$13.9M$6.3M$6.3M$5.2M$5.5M$6.1M$14.0M$9.6M
Operating income $10.1M$13.1M$7.5M$5.7M$6.2M$4.3M$2.5M$653.0K-$9.0M$472.3K
Interest expense $1.9M$1.4M$1.0M$0$25.0K$15.0K$47.0K$133.0K$112.0K$109.4K
Pre-tax income $8.2M$11.9M$7.0M$5.8M$6.7M$4.4M$2.6M$520.0K-$9.1M$368.1K
Income tax $1.9M$2.9M$1.7M$1.4M$1.3M$4.4M$7.0K$11.0K$689.0K$0
Net income $6.3M$9.0M$5.3M$4.4M$5.4M$8.8M$2.6M$509.0K$509.0K$368.1K
EPS, basic 0.680.980.590.971.238.342.480.37-0.930.04
EPS, diluted 0.630.910.540.891.137.762.330.37-0.930.04
Shares, diluted (wtd. avg.) 10.0M9.9M9.8M4,9754.8M1.1M1.1M1.1M10.5M10.3M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents —————$6.3M$265.0K$259.0K$1.3M$1.3M
Receivables $8.8M$1.6M$2.0M$705.0K$945.0K$1.4M$2.3M$3.2M$2.0M$2.6M
Inventory $21.3M$11.1M$9.1M$9.1M$6.5M$3.5M$3.2M$2.7M$2.9M$3.8M
Total current assets $33.1M$18.1M$14.7M$23.2M$17.7M$7.1M$6.4M$6.4M$6.3M$7.9M
Property, plant and equipment $128.0K$75.0K$137.0K$46.0K$70.0K$113.0K$161.0K$174.0K$296.0K$171.0K
Goodwill $19.4M$13.0M$13.3M$358.0K$358.0K$133.0K$225.0K$225.0K$225.0K—
Other intangibles $51.4M$26.2M$26.3M$150.0K$192.0K$0—$320.0K$225.0K$6.5M
Total assets $106.3M$58.5M$55.3M$25.7M$21.5M$7.7M$7.1M$7.1M$6.9M$15.4M
Accounts payable $6.9M$4.1M$3.3M$3.0M$2.9M$1.6M$2.6M$2.3M$3.0M$1.6M
Short-term debt ———————$0$415.0K$544.8K
Total current liabilities $21.6M$11.3M$10.3M$4.3M$4.1M$2.4M$3.9M$3.7M$6.0M$4.5M
Long-term debt —$8.6M$15.5M$0————$0$369.2K
Total liabilities $62.7M$22.4M$28.3M$4.3M$4.2M$3.1M$4.1M$3.9M$6.0M$4.8M
Retained earnings $11.9M$5.6M-$3.4M-$8.7M-$13.1M-$25.8M-$28.6M-$29.0M——
Total equity $43.6M$36.1M$27.0M$21.4M$17.3M$4.6M$3.0M$2.1M$912.0K$912.0K

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $7.4M$9.6M$4.2M$4.1M$4.5M$5.7M$2.3M$258.0K$666.0K$48.2K
Depreciation and amortisation $420.0K$108.0K$94.0K$66.0K$59.0K$38.0K$52.0K$69.0K$54.7K$56.2K
Stock-based compensation —————$29.0K$118.0K$130.0K——
Capital expenditure $42.0K$10.0K$106.0K$0———$0$185.0K$23.4K
Investing cash flow -$42.5M-$10.0K-$36.0M$0-$529.0K$0$0$4.0K-$185.0K-$23.4K
Financing cash flow $32.1M-$7.0M$20.3M-$750.0K-$390.0K$350.0K-$2.3M-$1.3M-$512.0K-$264.3K
Dividends paid —————$0$63.0K$0——
Buybacks ——$0$779.0K$444.0K$171.0K$1.5M$0$0$156.9K

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001437749-26-021797.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. 0 25M 50M 75M 100M Revenue, FY2016: 25.3M Gross profit, FY2016: 10.1M Net income, FY2016: 368.1K Revenue, FY2017: 17.8M Gross profit, FY2017: 5.1M Net income, FY2017: 509K Revenue, FY2018: 17.1M Gross profit, FY2018: 6.7M Net income, FY2018: 509K Revenue, FY2019: 19.1M Gross profit, FY2019: 8M Net income, FY2019: 2.6M Revenue, FY2020: 22.1M Gross profit, FY2020: 9.5M Net income, FY2020: 8.8M Revenue, FY2021: 27.9M Gross profit, FY2021: 12.5M Net income, FY2021: 5.4M Revenue, FY2022: 28.8M Gross profit, FY2022: 12M Net income, FY2022: 4.4M Revenue, FY2023: 52.7M Gross profit, FY2023: 21.4M Net income, FY2023: 5.3M Revenue, FY2024: 64.5M Gross profit, FY2024: 28.1M Net income, FY2024: 9M Revenue, FY2025: 81.5M Gross profit, FY2025: 31.5M Net income, FY2025: 6.3M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $25.3M $17.8M $17.1M $19.1M $22.1M $27.9M $28.8M $52.7M $64.5M $81.5M
Gross profit $10.1M $5.1M $6.7M $8.0M $9.5M $12.5M $12.0M $21.4M $28.1M $31.5M
Net income $368.1K $509.0K $509.0K $2.6M $8.8M $5.4M $4.4M $5.3M $9.0M $6.3M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Results announced Item 2.02
  • Regulation FD disclosure Item 7.01
  • Regulation FD disclosure Item 7.01
  • Results announced Item 2.02
  • Regulation FD disclosure Item 7.01
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Regulation FD disclosure Item 7.01
  • Results announced Item 2.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2833

TickerCompanyMarket capP/ERevenue growth
DFTX Definium Therapeutics, Inc. $4.79B — —
TRLV Trulieve Cannabis Corp. $2.09B — -0.4%
CRON Cronos Group Inc. $1.22B — 24.6%
TLRY Tilray Brands, Inc. $370.5M — 11.5%
CGC Canopy Growth Corp $282.6M — —
USNA USANA HEALTH SCIENCES INC $259.4M 24.2x 8.3%
NAGE Niagen Bioscience, Inc. $193.1M 12.2x 29.9%
BTMD biote Corp. $32.9M 1.6x -2.5%